How TRT Changed My Life? What Men Actually Notice on Testosterone Therapy, and When, According to the Trials

Search "how TRT changed my life" and the stories run together: more drive, better mood, more energy. Randomized trials back some of that. In the Testosterone Trials and TRAVERSE, testosterone therapy improved sexual desire, sexual activity and mood, and corrected anemia more often than placebo. It did not improve vitality scores, cognition or sleep quality.

How TRT changed my life is one of the most common things men type into a search bar before starting testosterone therapy, and the stories that come back are almost always glowing: more drive, a better mood, energy that feels like it belonged to someone ten years younger. Those accounts are real experiences, but they come from men who chose treatment, knew they were on it and decided to write about it. Randomized, placebo-controlled trials remove those biases, and they tell a narrower but more reliable story.

Two research programs carry most of the weight. The Testosterone Trials (TTrials), published by Snyder and colleagues in the New England Journal of Medicine in 2016, assigned 790 men aged 65 or older with testosterone below 275 ng/dL and symptoms to testosterone gel or placebo for 1 year. TRAVERSE, published by Lincoff and colleagues in the same journal in 2023, enrolled 5246 men aged 45 to 80 with confirmed low testosterone and heart disease or high cardiovascular risk. Together they show which parts of the TRT story hold up under a placebo comparison.

In the clinical trials, TRT changed men's sex lives and moods most clearly, and changed their energy and physical function far less than personal stories suggest. The TTrials found that raising testosterone to the mid-normal range for men 19 to 40 significantly increased sexual activity, sexual desire and erectile function. Men on testosterone also reported slightly better mood and fewer depressive symptoms than men on placebo.

The TTrials investigators were blunt about the limits. In their summary, raising testosterone for a year produced a moderate benefit for sexual function and some benefit for mood, "but no benefit with respect to vitality or walking distance." Vitality here was measured with a validated fatigue scale, the closest thing a trial has to the "I have my energy back" line that runs through so many TRT testimonials.

A 2026 narrative review by Braga and Basaria in the Journal of Clinical Endocrinology and Metabolism pulled the TTrials and TRAVERSE results together. Its conclusion: testosterone therapy improves sexual function and mood but not vitality, physical function or cognitive function, and it did not raise major cardiovascular events in men at high cardiovascular risk. The authors suggested treating the symptoms where testosterone has shown benefit and looking to other therapies for the rest.

Men on TRT usually notice changes in sexual interest and general wellbeing first, within the first month, while changes in body composition, blood counts and bone take months to years. That sequence comes from a 2011 review by Saad and colleagues in the European Journal of Endocrinology, which pooled published testosterone studies to map when each effect starts and when it peaks.

According to the Saad review, effects on sexual interest appear after 3 weeks and plateau at 6 weeks, while changes in erections and ejaculation may need up to 6 months. Quality of life effects show within 3-4 weeks. Effects on depressive mood become detectable after 3-6 weeks and reach their maximum after 18-30 weeks. The review also noted that timing varies a great deal between men, partly because of the testosterone preparation used.

The timeline above comes from a review of earlier studies, many of them small and uncontrolled, so it describes typical onset rather than guaranteed results. It is still a useful corrective to the before and after posts that compress everything into the first few weeks. Muscle and fat changes, for example, start within 12-16 weeks and keep settling for 6-12 months. Our guide to TRT delivery methods covers how injections, gels and pellets shape the hormone curve that drives this timing.

TRT does bring back sex drive in men with confirmed low testosterone and low libido, and the effect lasted at least two years in the largest trial that measured it. The TRAVERSE Sexual Function Study, published by Pencina and colleagues in the Journal of Clinical Endocrinology and Metabolism, enrolled 1161 men with low libido: 587 assigned to 1.62% testosterone gel and 574 to placebo gel.

Men on testosterone reported 0.49 more sexual acts per day than men on placebo at 6 months and 0.47 more at 12 months, and the difference held at 24 months. Testosterone also improved hypogonadal symptoms and sexual desire. It did not improve erectile function compared with placebo, which separates TRAVERSE from the older TTrials result. A man whose main complaint is erections, rather than desire, may get more from treatments aimed at blood flow, such as the options covered in our article on daily tadalafil.

TRT gives small improvements in mood and energy on average, not the dramatic turnaround many testimonials describe. In a TRAVERSE analysis by Bhasin and colleagues (JCEM, 2024), 2643 of 5204 men (50.8%) had significant depressive symptoms at the start. In that group, and across all participants, TRT was linked to "modest but significantly greater improvements in mood and energy but not cognition or sleep quality."

The same TRAVERSE analysis found that only 49 men (1.5%) met strict criteria for low-grade persistent depressive disorder, the chronic low mood once called dysthymia, and the trial showed no clear benefit in that small group. Low testosterone and low mood often travel together, but testosterone is not an antidepressant. Our deeper look at low testosterone and depression covers what the research shows about that overlap.

One finding may explain some of the energy stories. In men who started TRAVERSE with anemia, defined as hemoglobin below 12.7 g/dL, changes in hemoglobin were associated with changes in energy level. Men whose fatigue partly came from a low red blood cell count may feel a real difference once that count rises, which is a different mechanism from testosterone acting directly on mood or motivation.

TRT corrected anemia in a larger share of men than placebo did, at every time point measured. In the TRAVERSE anemia study by Pencina and colleagues (JAMA Network Open, 2023), 815 men had anemia at the start. At 6 months anemia had corrected in 41.0% of men on testosterone versus 27.5% on placebo, and at 12 months in 45.0% versus 33.9%. Among men without anemia, fewer on testosterone went on to develop it.

The chart above plots the correction rates reported by Pencina and colleagues among men with anemia in TRAVERSE: 42.8% versus 30.9% at 24 months, 43.5% versus 33.2% at 36 months and 44.6% versus 39.2% at 48 months. Fewer men remained in the study at the later visits, so the 48 month comparison rests on smaller numbers. The same red blood cell effect has a flip side: hematocrit can climb too high, which is why monitoring matters. Our article on hematocrit on TRT explains that side of the curve.

TRT did not clearly improve physical function in the TTrials. In the Physical Function Trial itself, the share of men who walked at least 50 m farther in a 6-minute walk test did not differ significantly between testosterone and placebo. When men from all three trials were pooled, 20.5% of men on testosterone reached that mark versus 12.6% on placebo.

The pooled TTrials result is a real signal but a modest one, and the primary analysis in the trial built to test physical function was negative. The Saad review places changes in lean mass and muscle strength within 12-16 weeks, but more muscle on a scan does not automatically mean a man moves better. Resistance training is the more dependable lever for strength, with or without TRT, as our guide to lifting and testosterone after 40 explains.

TRT did not increase major heart events in TRAVERSE, but men on testosterone had more fractures and a few other adverse events. TRAVERSE used 1.62% testosterone gel, adjusted to keep levels between 350 and 750 ng/dL. Over a mean follow-up of 33.0 months, a heart attack, stroke or cardiovascular death occurred in 182 men (7.0%) on testosterone and 190 men (7.3%) on placebo, a hazard ratio of 0.96. Atrial fibrillation, acute kidney injury and pulmonary embolism were more common on testosterone.

The TRAVERSE fracture study by Snyder and colleagues (NEJM, 2024) was expected to show fewer fractures, because testosterone improves bone density. It found the opposite direction. After a median follow-up of 3.19 years, a clinical fracture occurred in 91 men (3.50%) on testosterone and 64 men (2.46%) on placebo, a hazard ratio of 1.43. The authors concluded testosterone did not lower fracture incidence, and the rate was numerically higher on testosterone.

Many men say TRT changed their life because the changes it reliably produces, in libido, sexual activity and mood, are the ones men feel most personally. A man whose desire returns after years of feeling flat has every reason to call that life-changing, and the TRAVERSE Sexual Function Study suggests that improvement can last at least 24 months.

Other parts of the testimonial pattern are harder to separate from expectation. Men who start TRT often change other things at the same time: they begin lifting, sleep more, drink less or lose weight. Placebo effects are also real in open treatment, which is why the TTrials and TRAVERSE compared testosterone with a placebo gel. In both programs, some outcomes that men often credit to TRT, such as energy, cognition and sleep, moved little or not at all once that comparison was made.

A man starting TRT should track the specific symptoms he wants to change plus the blood markers his doctor monitors, so he can judge his own result against the trial evidence. The Endocrine Society recommends a standardized monitoring plan that evaluates symptoms, side effects and adherence, measures serum testosterone and hematocrit, and assesses prostate cancer risk during the first year of treatment. The guideline also suggests aiming for testosterone in the mid-normal range rather than pushing it higher.

• Sexual desire and frequency of sexual activity, noted weekly for the first few months, since the Saad review places the plateau for sexual interest at about 6 weeks.
• Mood, using the same simple rating each week, remembering that the maximum effect on depressive mood took 18-30 weeks in the Saad review.
• Hemoglobin and hematocrit at the intervals your doctor sets, because the red blood cell response is evident at 3 months and peaks at 9-12 months.
• PSA, which tends to rise slightly and plateau at 12 months according to the Saad review. Our PSA on TRT guide explains how to read the change.
• Training logs and waist measurements, which show whether body composition is moving, rather than the scale alone.

Writing these down before the first dose gives a man his own before and after record, which is far more useful than comparing himself with anonymous posts. It also shapes a better conversation with the prescribing doctor at each review, especially for men also dealing with the mid-life changes described in our article on dating after 45.

This article is for educational purposes only and is not medical advice. It does not diagnose, treat, cure or prevent any disease. Testosterone therapy is a prescription treatment with real risks, so speak with a licensed physician before starting, stopping or changing any hormone therapy.

• Snyder PJ et al. Effects of Testosterone Treatment in Older Men. New England Journal of Medicine, 2016. https://doi.org/10.1056/NEJMoa1506119
• Saad F et al. Onset of effects of testosterone treatment and time span until maximum effects are achieved. European Journal of Endocrinology, 2011. https://doi.org/10.1530/EJE-11-0221
• Lincoff AM et al. Cardiovascular Safety of Testosterone-Replacement Therapy. New England Journal of Medicine, 2023. https://doi.org/10.1056/NEJMoa2215025
• Pencina KM et al. Effect of Testosterone Replacement Therapy on Sexual Function and Hypogonadal Symptoms in Men with Hypogonadism. Journal of Clinical Endocrinology and Metabolism, 2024. https://doi.org/10.1210/clinem/dgad484
• Bhasin S et al. Depressive Syndromes in Men With Hypogonadism in the TRAVERSE Trial: Response to Testosterone-Replacement Therapy. Journal of Clinical Endocrinology and Metabolism, 2024. https://doi.org/10.1210/clinem/dgae026
• Pencina KM et al. Efficacy of Testosterone Replacement Therapy in Correcting Anemia in Men With Hypogonadism: A Randomized Clinical Trial. JAMA Network Open, 2023. https://doi.org/10.1001/jamanetworkopen.2023.40030
• Snyder PJ et al. Testosterone Treatment and Fractures in Men with Hypogonadism. New England Journal of Medicine, 2024. https://doi.org/10.1056/NEJMoa2308836
• Braga M, Basaria S. Key Findings on the Efficacy and Safety of Testosterone Therapy from Two Large Randomized Trials. Journal of Clinical Endocrinology and Metabolism, 2026. https://doi.org/10.1210/clinem/dgag397
• Bhasin S et al. Testosterone Therapy in Men With Hypogonadism: An Endocrine Society Clinical Practice Guideline. Journal of Clinical Endocrinology and Metabolism, 2018. https://doi.org/10.1210/jc.2018-00229

Continue Reading

Related Articles

Guide

Dating After 45: Why Your Body Changed Faster Than Your Life Did

9 min read

Read Article →

Men's Health

Low Testosterone and Depression in Men Over 40: What the Research Actually Shows

11 min read

Read Article →

Hormones

Hematocrit on TRT: What a Rising Blood Count Actually Means

12 min read

Read Article →